[康霈*] Phase 3 clinical trial for CBL-514 injection to reduce abdominal subcutaneous fat approved in Canada.

1. Date of event: 2026/05/28. 2. Drug name: CBL-514. 3. Purpose: Reduce subcutaneous fat, improve cellulite, treat Dercum's disease. 4. Development stages: Phase 1 completed, Phase 2 completed, Phase 3 ongoing. 5. Current status: The second pivotal Phase 3 trial (CBL-0302) received CTA approval from Health Canada on May 28, 2026. The study uses MRI and PR-AFRS as primary endpoints, targeting 320 subjects in the US, Canada, and Australia. 6. Next steps: Follow clinical trial progress. 7. Market status: High demand for non-invasive fat reduction, yet current products have limitations. 8. Risk warning: Drug development is long and costly; investors should exercise caution.